What Is the CJC-1295 No DAC + Ipamorelin Blend?

The CJC-1295 No DAC + Ipamorelin blend puts two growth-hormone secretagogues in one vial: a GHRH-receptor analog and a selective ghrelin-receptor agonist. They hit different receptors on the same axis, which is why researchers study them together rather than alone. This guide covers what each half does, how the combination is described in the literature, the reconstitution math, and the limits of what's actually known. Research use only. (Bowers 1990)

Composition: A single 10 mg lyophilized vial holds CJC-1295 No DAC (Mod GRF 1-29), 5 mg plus Ipamorelin, 5 mg. CJC-1295 No DAC binds the GHRH receptor; Ipamorelin binds the ghrelin receptor (GHSR-1a). Two receptors, one growth-hormone axis.

The Short Answer

This blend combines a short-acting GHRH analog (CJC-1295 No DAC, also called Mod GRF 1-29) with a selective GHRP-class ghrelin-receptor agonist (Ipamorelin). GHRH-receptor signaling and ghrelin-receptor signaling drive growth-hormone release through separate pathways, and the two have been reported to produce a larger combined GH response than either input on its own. The "No DAC" form is short-acting by design, so its profile sits closer to native GHRH than the longer-lasting DAC version. Educational content only. (Bowers 1990)

Property	Detail
Components	CJC-1295 No DAC (Mod GRF 1-29) 5 mg + Ipamorelin 5 mg
Total per vial	10 mg lyophilized powder
Targets	GHRH receptor (CJC-1295 No DAC) + GHSR-1a / ghrelin receptor (Ipamorelin)
CAS	CJC-1295 No DAC: 863288-34-0; Ipamorelin: 170851-70-4
CJC-1295 No DAC formula	C152H252N44O42 (~3368 g/mol)
Ipamorelin formula	C38H49N9O5 (~711.9 g/mol)
Typical diluent (educational)	Bacteriostatic Water for Injection, USP (0.9–1.1% benzyl alcohol; multi-dose)
Example concentration (educational)	10 mg vial + 2.0 mL → 5.0 mg/mL total (2.5 mg/mL of each component); math example, not dosing
Storage	Lyophilized at ≤ −20 °C, protected from light; reconstituted solution at 2–8 °C short-term, per SOP

Sources: chemical identity from PubChem; receptor pharmacology from peer-reviewed GH literature; diluent identity from DailyMed (USP). (PubChem)

Key Concepts

The Two Components

CJC-1295 No DAC is a stabilized analog of GHRH(1-29), the active fragment of growth-hormone-releasing hormone. It carries four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that slow enzymatic breakdown by DPP-IV, so it survives longer than native GRF(1-29) while keeping a short overall action. It binds the GHRH receptor and works through the cAMP pathway in pituitary somatotrophs. The alternate name you'll see is Mod GRF 1-29. One point matters for reading the evidence: most published human pharmacology covers the DAC version (the one with Drug Affinity Complex, which extends the half-life to days), not the No-DAC form. Teichman and colleagues studied DAC CJC-1295 in a randomized trial and reported prolonged GH and IGF-I elevation. (Teichman 2006)

Ipamorelin is a selective ghrelin-receptor (GHSR-1a) agonist from the GHRP class. It triggers a brief, pulse-like GH release and, in the original pharmacology, did so without the ACTH and cortisol bumps seen with older GHRPs like GHRP-6. It's a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a peptide half-life near two hours. (Raun 1998)

How the Combination Is Described

The rationale for pairing a GHRH analog with a GHRP goes back to Bowers and colleagues, who showed that GHRH and a GHRP acting together release more growth hormone than the sum of each given alone. The two signals are mechanistically distinct: GHRH raises cAMP, while the ghrelin receptor works through phospholipase-C and calcium, and ghrelin-pathway activity also blunts somatostatin's inhibitory tone. Hitting both at once is the whole reason these two are vialed together. (Bowers 1990)

A caution on framing. The supra-additive GH response is well documented for the GHRH-plus-GHRP class. Specific human data on the No-DAC CJC-1295 paired with Ipamorelin is thin, so the mechanism is the honest basis for interest here, not finished clinical proof. (GHS receptor review)

Step-by-Step: How to Work With the Blend

Educational note: This is a research peptide blend, not approved for human therapeutic use. The steps below are educational and not medical advice. Follow your institution's SOPs, the product COA, and applicable regulations.

1) Verify identity and integrity

Check the COA for both components, lot, mass, and purity. Inspect the lyophilized cake and the vial seal. Cross-check identifiers: CJC-1295 No DAC CAS 863288-34-0, Ipamorelin CAS 170851-70-4. The No-DAC CAS matters, since the with-DAC form (446036-97-1) is a different compound. (PubChem)

2) Plan the concentration math

Decide a working concentration before opening the vial. Example: 10 mg total in 2.0 mL bacteriostatic water gives 5.0 mg/mL, which is 2.5 mg/mL of CJC-1295 No DAC and 2.5 mg/mL of Ipamorelin. On a U-100 insulin syringe, one unit (0.01 mL) draws 50 mcg of total blend, split 25 mcg / 25 mcg. This is reconstitution arithmetic, kept separate from any dosing discussion.

3) Choose the diluent

Bacteriostatic Water for Injection, USP (sterile water with 0.9–1.1% benzyl alcohol) is the common multi-dose diluent for injectable research formats. Validate it against your application and SOP; bacteriostatic diluents are not for neonatal use. (DailyMed)

4) Reconstitute gently

Bring vial and diluent to room temperature, swab the stopper, and add the water slowly down the inside glass wall. Swirl; don't shake. Peptide solutions aggregate under mechanical stress, and two peptides in one vial is no exception.

5) Label and store

Record both compounds, lot, concentration, diluent, and the date and time of reconstitution. Store lyophilized material at ≤ −20 °C away from light. Keep the reconstituted solution at 2–8 °C for short-term use and limit freeze-thaw cycles, per SOP.

6) Dispose responsibly

Follow biosafety and hazardous-waste procedures and log the disposal.

Comparison & Alternatives

Option	What it is	Profile
CJC-1295 No DAC + Ipamorelin	GHRH analog + selective GHRP	Two complementary inputs; short-acting GHRH half, brief GH pulse from the GHRP half
Ipamorelin alone	Selective GHSR-1a agonist	Single short GH pulse; the most GH-selective first-generation GHRP
CJC-1295 No DAC alone	Short-acting GHRH analog	GHRH-receptor input without the ghrelin-pathway component
CJC-1295 DAC	Long-acting GHRH analog	Days-long GH/IGF-I elevation; changes timing rather than pulse shape (Teichman 2006)

The blend's appeal is the two-receptor design. Ipamorelin on its own gives a clean, selective pulse; the No-DAC GHRH half adds a second, independent push on the same axis. The DAC version is a different research question entirely, since its long half-life shifts the study from "pulse shape" to "sustained exposure."

FAQs

What is the CJC-1295 No DAC + Ipamorelin blend?
It is a research-grade combination of two growth-hormone secretagogues in one 10 mg vial: 5 mg of CJC-1295 No DAC (a GHRH-receptor analog) and 5 mg of Ipamorelin (a selective ghrelin-receptor agonist). The two act on separate receptors of the same growth-hormone axis. It is sold for laboratory research only and is not an approved medication.

Why combine a GHRH analog with a GHRP?
Because they work through different receptors. CJC-1295 No DAC signals through the GHRH receptor and the cAMP pathway; Ipamorelin signals through the ghrelin receptor and the calcium pathway, and also reduces somatostatin's braking effect. Bowers and colleagues showed that a GHRH plus a GHRP together release more growth hormone than either alone, which is the documented basis for pairing this class.

What does "No DAC" mean?
DAC stands for Drug Affinity Complex, a modification that binds CJC-1295 to albumin and stretches its half-life to several days. The No-DAC form (Mod GRF 1-29) omits that, so it acts over a short window closer to native GHRH. Most published human trials used the DAC version, so No-DAC claims should lean on the shared GHRH-analog mechanism rather than No-DAC-specific human data.

How is the blend reconstituted?
A common educational example: add 2.0 mL of bacteriostatic water to the 10 mg vial for 5.0 mg/mL total, which is 2.5 mg/mL of each component. On a U-100 syringe, one unit draws 50 mcg of total blend. This is reconstitution math for reference, not a dosing recommendation.

Is the blend approved for human use?
No. Both components are research compounds, not approved drugs. Growth-hormone secretagogues, including Ipamorelin and GHRH analogs, are also on the WADA Prohibited List at all times, so anyone working with athlete populations must check current antidoping rules.

How is it stored?
Keep the lyophilized vial at or below −20 °C, protected from light. After reconstitution, hold the solution at 2–8 °C for short-term use and minimize freeze-thaw cycles. The benzyl alcohol in bacteriostatic water limits microbial growth during multi-day handling, but the COA and your SOP govern the specifics.

Next Steps

What Is Ipamorelin? — deep dive on the selective GHRP half of the blend
What Is Tesamorelin? — a related GHRH-analog for mechanism comparison

Takeaway: The CJC-1295 No DAC + Ipamorelin blend is a two-receptor research tool: a short-acting GHRH analog and a selective ghrelin-receptor agonist studied for their combined effect on the GH axis. The mechanism is well grounded; No-DAC-specific human proof is not. Educational content only, no medical advice. (Bowers 1990)